To stop or not to stop immunotherapy after 2 years in Non Small Cell Lung Cancer (NSCLC)? Results of a cross sectional survey among French thoracic oncologist.

S. Storme (Lyon, France), D. Debieuvre (Mulhouse, France), P. Souquet (Lyon, France), S. Couraud (Lyon, France)

Source: International Congress 2022 – Identification of therapeutic strategies in lung cancer

Session: Identification of therapeutic strategies in lung cancer
Session type: Thematic Poster
Number: 1915

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Storme (Lyon, France), D. Debieuvre (Mulhouse, France), P. Souquet (Lyon, France), S. Couraud (Lyon, France). To stop or not to stop immunotherapy after 2 years in Non Small Cell Lung Cancer (NSCLC)? Results of a cross sectional survey among French thoracic oncologist.. 1915

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.